Heart shock drug showdown: which saves more lives?
NCT ID NCT07562932
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study tests whether norepinephrine or dopamine is better as the first drug for adults with cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 512 participants will be randomly assigned to one of the two drugs and monitored for survival, complications, and recovery. The goal is to find which treatment reduces death and prevents the shock from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chonnam National University Hospital
Gwangju, 61469, South Korea
Conditions
Explore the condition pages connected to this study.